Sugi Predict

Sugi Predict / Compounds / SCHEMBL8909697

SCHEMBL8909697

SCHEMBL8909697

O=S(=O)(O)Nc1cc[c]cc1

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PTPRB P23467 10/20 0.39
▸ PTPN1 P18031 2/20 0.36
▸ PTPN2 P17706 1/20 0.36
▸ PTPRA P18433 1/20 0.36
▸ CA1 P00915 3/20 0.35
▸ CA2 P00918 3/20 0.35
▸ KEAP1 Q14145 2/20 0.33
▸ ACP1 P24666 2/20 0.32
▸ IL1RN P18510 1/20 0.32
▸ ERAP1 Q9NZ08 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ GFER P55789 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4455223 0.82 PTPRB (0.48) PTPRBPTPN1PTPN2PTPRACA1
SCHEMBL1975965 0.76 CA1 (0.60) CA1CA2
SCHEMBL1621848 0.76 CA1 (0.35) CA1CA2KEAP1IL1RNERAP1
SCHEMBL6232580 0.76 PTPN11 (0.34) PTPN1CA1CA2KEAP1IL1RN
SCHEMBL20032 0.76 KEAP1 (0.60) CA1CA2KEAP1ALDH1A1GAA
SCHEMBL28350553 0.76 ALDH1A1 (0.48) CA1CA2KEAP1IL1RNERAP1
SCHEMBL146561 0.75 CA2 (0.58) PTPRBPTPN1PTPN2PTPRACA1
Benzene SCHEMBL6746153 0.75 CA2 (0.58) PTPRBPTPN1PTPN2PTPRACA1
SCHEMBL4210399 0.74 ACP1 (0.36) PTPRBPTPN1PTPN2PTPRACA1
Methane SCHEMBL3339448 0.73 CA2 (0.56) PTPRBPTPN1PTPN2PTPRACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4153237-A1 METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME WITH ACTIVATORS OF TIE-2 EyePoint Pharmaceuticals, Inc. (US) 2023-03-29 — — EP claimed
US-20220211675-A1 TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL EyePoint, Inc. 2022-07-07 — — US claimed
WO-2022133078-A1 DOSAGE FORMS OF TIE-2 ACTIVATORS EyePoint Pharmaceuticals, Inc. (US) 2022-06-23 — — WO claimed
EP-3956021-A1 METHODS OF TREATING HYPERTENSION WITH ACTIVATORS OF TIE-2 EyePoint Pharmaceuticals, Inc. (US) 2022-02-23 — — EP claimed
US-11253502-B2 Tie-2 activators targeting the Schlemm's canal EyePoint Pharmaceuticals, Inc. (US) 2022-02-22 — — US claimed
US-20210386713-A1 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 EyePoint, Inc. 2021-12-16 — — US claimed
WO-2021236985-A1 METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME WITH ACTIVATORS OF TIE-2 Aerpio Pharmaceuticals, Inc. (US) 2021-11-25 — — WO claimed
US-20210130341-A1 HPTP-BETA INHIBITORS EyePoint Pharmaceuticals, Inc. 2021-05-06 — — US claimed
EP-3759234-A1 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPSS INHIBITORS Aerpio Pharmaceuticals, Inc. (US) 2021-01-06 — — EP claimed
US-10858354-B2 HPTP-Beta inhibitors Aerpio Pharmaceuticals, Inc. (US) 2020-12-08 — — US claimed
US-20150259335-A1 HPTP-BETA INHIBITORS AERPIO THERAPEUTICS, INC. 2015-09-17 — — US claimed
WO-2015138882-A1 HPTP-BETA INHIBITORS AERPIO THERAPEUTICS, INC. (US) 2015-09-17 — — WO claimed
US-20140275103-A1 Compositions, formulations and methods for treating ocular diseases AERPIO THERAPEUTICS INC. (US) 2014-09-18 — — US claimed
WO-2014145068-A1 COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES AERPIO THERAPEUTICS INC. (US) 2014-09-18 — — WO claimed
CN-102731343-A Nitrogen atom-polysubstituted micro-molecular organic aryl amide compounds and derivatives thereof, and application and preparation method thereof UNIV EAST CHINA NORMAL 2012-10-17 — — CN claimed
CN-102307474-A Imidazopyrazine SYK inhibitors CGI PHARMACEUTICALS INC 2012-01-04 — — CN claimed
CN-1154699-C Reactive diamine-linked azo dyes �����ɷ� 2004-06-23 — — CN claimed
US-4684664-A BACTERICIDES, FUNGICIDES KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1987-08-04 — — US claimed
EP-0012611-B1 ELECTROPHOTOGRAPHIC ELEMENT Ricoh Company, Ltd (JP) 1983-10-05 — — EP claimed
EP-0012611-A2 Electrophotographic element Ricoh Company, Ltd (JP) 1980-06-25 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210386713-A1 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 TIE1, TEK, VASP PTPRB 1545/4885PTPN1 4212/4885PTPN2 3296/4885
US-20150259335-A1 HPTP-BETA INHIBITORS TEK, TIE1, PITPNB PTPRB 718/4885PTPN1 3035/4885PTPN2 2111/4885
US-20220211675-A1 TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL TIE1, TEK, TGFB2 PTPRB 840/4885PTPN1 3438/4885PTPN2 2323/4885
US-20140275103-A1 Compositions, formulations and methods for treating ocular diseases TIE1, TEK, KDR PTPRB 609/4885PTPN1 2139/4885PTPN2 1170/4885
US-11253502-B2 Tie-2 activators targeting the Schlemm's canal TIE1, TEK, TGFB2 PTPRB 840/4885PTPN1 3438/4885PTPN2 2323/4885
US-20210130341-A1 HPTP-BETA INHIBITORS TEK, TIE1, PITPNB PTPRB 718/4885PTPN1 3035/4885PTPN2 2111/4885
US-10858354-B2 HPTP-Beta inhibitors TEK, TIE1, PITPNB PTPRB 718/4885PTPN1 3035/4885PTPN2 2111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.